PellePharm is a biotechnology company committed to targeting rare dermatological diseases, including Gorlin Syndrome and Basal Cell Carcinomas, at the source.Learn More
At PellePharm, we are proud to work in partnership with the Gorlin Syndrome Alliance, The Gorlin Syndrome Group, and LEO Pharma to advance R&D efforts that we hope will be transformative for people affected by Gorlin Syndrome.
We currently are looking for qualified candidatesJoin Us
“From our co-discovery of the underlying genetic defect, through over two decades of preclinical research with hedgehog inhibitors and our recent clinical trials, our team at PellePharm is deeply committed to delivering a safe and effective therapy for people living with Gorlin Syndrome.”
– ERVIN EPSTEIN, MD
PellePharm is focused on developing patidegib, an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications.Learn More
With no FDA-approved drugs available for Gorlin Syndrome, also known as Basal Cell Carcinoma Nevus Syndrome (BCCNS), the standard of care is surgery.Learn More